Please assess the completion status of the following clinical trial:

Trial Title: Observational Study in CLL Patients Receiving BR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of chronic lymphocytic leukemia~* Patients treated with first-line BR for active disease requiring treatment~* Cumulative Illness Rating Scale (CIRS) \> 6~* Informed consent to data collection~Exclusion Criteria:~* Patients treated with BR within prospective clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BR in CLL (Type: None): Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).